Cargando…

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

OBJECTIVES: Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA during the initial 24 months of modern treat-to-target therapy and predictors of fatigue after 24 mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holten, Karen, Paulshus Sundlisater, Nina, Lillegraven, Siri, Sexton, Joseph, Nordberg, Lena Bugge, Moholt, Ellen, Hammer, Hilde Berner, Uhlig, Till, Kvien, Tore K, Haavardsholm, Espen A, Aga, Anna-Birgitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862091/ https://www.ncbi.nlm.nih.gov/pubmed/34389605 http://dx.doi.org/10.1136/annrheumdis-2021-220750

Ejemplares similares

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
por: Sundin, Ulf, et al.
Publicado: (2021)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study
por: Holten, Karen, et al.
Publicado: (2018)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs
por: Pukšić, Silva, et al.
Publicado: (2018)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
por: Uhlig, Till, et al.
Publicado: (2022)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study
por: Uhlig, Till, et al.
Publicado: (2021)

Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study
por: van Steenbergen, Hanna W, et al.
Publicado: (2015)

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities
por: Kvien, Tore K, et al.
Publicado: (2020)

Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT)
por: Hewlett, Sarah, et al.
Publicado: (2019)

Value of imaging detected joint inflammation in explaining fatigue in RA at diagnosis and during the disease course: a large MRI study
por: Matthijssen, X M E, et al.
Publicado: (2021)

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial
por: Haavardsholm, Espen A, et al.
Publicado: (2016)

Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2015)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
por: Kolan, Shrikant S., et al.
Publicado: (2022)

Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment
por: de Thurah, Annette, et al.
Publicado: (2020)

Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
por: Saevarsdottir, Saedis, et al.
Publicado: (2022)

Development of a feasible and responsive ultrasound inflammation score for rheumatoid arthritis through a data-driven approach
por: Aga, Anna-Birgitte, et al.
Publicado: (2016)

Recognition of Amino Acid Motifs, Rather Than Specific Proteins, by Human Plasma Cell–Derived Monoclonal Antibodies to Posttranslationally Modified Proteins in Rheumatoid Arthritis
por: Steen, Johanna, et al.
Publicado: (2019)

Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
por: Semb, Anne Grete, et al.
Publicado: (2021)

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci
por: Plant, Darren, et al.
Publicado: (2011)

Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis
por: Farragher, Tracey M, et al.
Publicado: (2008)

Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort
por: Plant, Darren, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_743msvc000v5q8fbdofbgjjrqj